Drug firm Venus Remedies today said it had launched its 'Achnil' injection, a pain killer, in the country. The company has launched a novel formulation, 'Achnil' -- a brand of Aceclofenac injection in India, the company said in a statement.
Venus Remedies joint managing director Manu Chaudhry said: "This novel formulation based on NDDS (Novel Drug Delivery System) technology will fill in the gap of long-standing demand for better pain management therapies, especially for the aged population."
She further added the product would not only reduce the number of pricks, but will also drastically reduce the side effects associated with the use of non-steroidal, anti-inflammatory drugs (NSAIDs).
According to the firm, the new product gives instant relief from acute pain and is effective for the next 24 hours against the conventional daily dose of three injections of diclofenac given every 8 hours.
It took more than seven years for the successful completion of phase-I, phase-II and phase-III clinical trials and regulatory approvals from DCGI for this product, it said.
Apart from India, the company also plans to launch the product in other markets worldwide, the company added.
Shares of Venus Remedies were being quoted at Rs 192 apiece in late afternoon trade on the Bombay Stock Exchange today, up 0.42% from their previous close.
